Breast cancer drug gets breakthrough label
April 10, 2013 (NEW YORK) -- Pfizer Inc. says its experimental pill for advanced, often deadly breast cancer has been designated as a breakthrough therapy by the Food and Drug Administration.
Pfizer shares jumped nearly 3 percent following the news.
The breakthrough designation is meant to speed up development and review of experimental treatments seen as big advances.
The drug, palbociclib, is being evaluated as an initial treatment for a subgroup that includes about 60 percent of postmenopausal women whose breast cancer is locally advanced or has spread elsewhere in the body. Their tumors are fueled by the hormone estrogen.
Pfizer is currently running a late-stage study of palbociclib, comparing its effects in combination with letrozole with the effects of letrozole alone. Letrozole, sold under the brand Femara, blocks production of estrogen.
- Oil slicks found in hunt for missing Malaysia jet 8 min ago
- Man, 29, dead after ejected from SUV on I-57 50 min ago
- HS basketball player shines despite disabilty
- ABC7 First Alert Weather Forecast
- 'El Chapo' lieutenant wants trial in Chicago
- Teacher's aide posed as teen to meet girls online
- CTA Green Line briefly interrupted 43 min ago
- Dog rescue underway at Lake Michigan
- Free small business expo begins in Chicago 12 min ago
- Gun hidden in sock kills woman at thrift store
- Kennedy reversible lanes closed at times this weekend
- Russia reinforces military presence in Crimea, Ukraine 3 min ago
- Mom accused of driving into surf goes before judge
- abcnews: Family Sickened By Meat Laced with LSD
- Man, 29, dead after ejected from SUV on I-57
50 min ago